Menu
Back to Journals » Biologics: Targets and Therapy » Volume 6
Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
Authors Kobrynski L
Received 8 May 2012
Accepted for publication 7 June 2012
Published 24 August 2012 Volume 2012:6 Pages 277—287
DOI https://doi.org/10.2147/BTT.S25188
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Lisa Kobrynski
Department of Pediatrics, Emory University, Atlanta, GA, USA
Abstract: Since the 1950s, replacement of immunoglobulin G using human immunoglobulin has been the standard treatment for primary immunodeficiency diseases with defects in antibody production. These patients suffer from recurrent and severe infections, which cause lung damage and shorten their life span. Immunoglobulins given intravenously (IVIG) every 3–4 weeks are effective in preventing serious bacterial infections and improving the quality of life for treated patients. Administration of immunoglobulin subcutaneously (SCIG) is equally effective in preventing infections and has a lower incidence of serious adverse effects compared to IVIG. The tolerability and acceptability of SCIG has been demonstrated in numerous studies showing improvements in quality of life and a preference for subcutaneous immunoglobulin therapy in patients with antibody deficiencies.
Keywords: primary immunodeficiency diseases, subcutaneous immunoglobulin, immunoglobulin G
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.